Cell therapy company Chimeric Therapeutics (ASX:CHM) has announced the appointment of Eric Sullivan as a non-executive director.
Chimeric said Mr Sullivan brings an impressive background in the biotechnology sector, having served in senior finance and operations leadership roles across a number of high-growth public companies, including bluebird bio, Merrimack Pharmaceuticals and TCR2 Therapeutics.
His experience with private companies, such as Oncorus, Gemini Therapeutics, and Triplet Therapeutics, underpins his expertise in financial planning, fundraising, board management and investor relations.
Chimeric executive chairman Paul Hopper said, “Mr Sullivan brings in a new skillset and experience in the US biotechnology market which will be beneficial to our strategy at Chimeric. He has a proven track record, particularly in financial planning, operations, and strategic transactions, which will all be invaluable as we continue to grow and advance our pipeline."
Mr Sullivan replaces Cindy Elkins, who is stepping down from the chimeric board of directors.
“I would like to thank Cindy for her contributions to Chimeric over the last two and a half years,” said Mr Hopper. “She has assisted in guiding Chimeric Therapeutics through its formative years, and her expertise and leadership is appreciated. On behalf of the entire board and team, I wish Cindy the very best in her future endeavours.”